Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (12354)	11/29/1999 8:23:00 AM
From: Tharos	Respond to of 17367

New Antifungal Agents Show Activity Against Fluconazole-Resistant Candida WESTPORT, Nov 23 (Reuters Health) - Spanish investigators describe two new antifungal agents that exhibit superior or comparable in vitro activity against Candida. isolates from HIV-infected patients when compared with currently available agents. These two new agents also appear to be active against fluconazole-resistant strains. Dr. M. Chavez of the Hospital Universitario de Valme, in Sevilla, and associates examined the in vitro activity of voriconazole (UK-109,496) and LY303366 against 219 clinical yeast isolates recovered from the oral cavities of HIV-infected patients. Most of the isolates (183) were Candida albicans. Dr. Chavez used the broth microdilution method as set forth by the National Committee of Clinical Laboratory Standards to compare the efficacy of these two new agents with that of fluconazole, itraconazole, 5-fluorocytosine (5FC) and amphotericin B. "The in vitro activity of voriconazole (UK-109,496)...and LY303366...against clinical isolates of Candida spp. was excellent and comparable with that of amphotericin B...and better than those of fluconazole...itraconazole...and 5FC," they report in the November issue of the Journal of Antimicrobial Chemotherapy. The investigators point out that the mode of action of voriconazole (UK-109,496) and LY303366 gives these agents a wide spectrum of activity compared with fluconazole. Both agents showed"...very potent activity...against isolates of C. krusei and C. glabrata, species usually considered resistant to azoles such as fluconazole." Dr. Chavez's group believes the "excellent" activity of these two agents against fluconazole-resistant strains "...may have important clinical implications for the management of Candida spp. infections." Clinical trials of voriconazole and LY303366, which are both available in oral and parenteral formulations, are currently underway. J Antimicrob Chemother 1999;697-700. Copyright ¸ 1999 Reuters Ltd. id.medscape.com